Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Ilson
    Ilson
  4. Hricak
    Hricak
  5. Lee
    Lee
  6. Riely
    Riely
  7. Abou-Alfa
    Abou-Alfa
  8. Lewis
    Lewis
  9. Kingham
    Kingham
  10. Sklar
    Sklar

Groups

  1. Department of Medicine (236)
  2. Solid Tumor Oncology Division (195)
  3. Surgery (69)
  4. GSK Faculty (54)
  5. Genitourinary Oncology Service (53)
  6. Population Sciences Research Program (49)
  7. Hematologic Malignancies, Division of (47)
  8. Survivorship Research (45)
  9. Gastrointestinal Oncology Service (44)
  10. Center for Hematologic Malignancies (34)
Search Within
  1. "Lancet Oncology"
Formats
  1. Journal Article (324)
  2. Editorial (25)
  3. Review (24)
  4. Correspondence (22)
  5. Guidelines (12)
  6. Research Letter (1)
Groups
  1. Department of Medicine (236)
  2. Solid Tumor Oncology Division (195)
  3. Surgery (69)
  4. GSK Faculty (54)
  5. Genitourinary Oncology Service (53)
  6. Population Sciences Research Program (49)

More Groups

People
  1. Robert Motzer (18)
  2. Howard Scher (14)
  3. David Ilson (12)
  4. Edward Christopher Dee (11)
  5. Gregory Riely (11)
  6. Hedvig Hricak (11)

More People

Years
  1. 2025 (33)
  2. 2024 (28)
  3. 2023 (15)
  4. 2022 (27)
  5. 2021 (33)
  6. 2020 (35)

More Years

Publications
  1. Lancet Oncology (408)

Results (408)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): A randomised, open-label, phase 3 trial from the Children's Oncology Group
    Journal Article

    Gupta, A. A.; Xue, W.; Harrison, D. J.; Hawkins, D. S.; Dasgupta, R.; Wolden, S.; Shulkin, B.; Qumseya, A.; Routh, J. C.; MacDonald, T.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: Workforce challenges and training in the age of theranostics
    Review

    Scott, A. M.; Zeglis, B. M.; Lapi, S. E.; Scott, P. J. H.; Windhorst, A. D.; Abdel-Wahab, M.; Giammarile, F.; Piaez, D.; Jalilian, A.; Knoll, P.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Production and regulatory issues for theranostics
    Review

    Giammarile, F.; Paez, D.; Zimmermann, R.; Cutler, C. S.; Jalilian, A.; Korde, A.; Knoll, P.; Ayati, N.; Lewis, J. S.; Lapi, S. E.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): An international, phase 2 study
    Journal Article

    Li, B. T.; Meric-Bernstam, F.; Bardia, A.; Naito, Y.; Siena, S.; Aftimos, P.; Anderson, I.; Curigliano, G.; de Miguel, M.; Kalra, M.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): A single-arm, multicentre, phase 2 trial
    Journal Article

    Necchi, A.; Roumiguié, M.; Kamat, A. M.; Shore, N. D.; Boormans, J. L.; Esen, A. A.; Lebret, T.; Kandori, S.; Bajorin, D. F.; Krieger, L. E. M.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Recent advances and impending challenges for the radiopharmaceutical sciences in oncology
    Review

    Lapi, S. E.; Scott, P. J. H.; Scott, A. M.; Windhorst, A. D.; Zeglis, B. M.; Abdel-Wahab, M.; Baum, R. P.; Buatti, J. M.; Giammarile, F.; Kiess, A. P.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
    Guidelines

    Rodriguez-Otero, P.; Usmani, S.; Cohen, A. D.; van de Donk, N. W. C. J.; Leleu, X.; Gállego Pérez-Larraya, J.; Manier, S.; Nooka, A. K.; Mateos, M. V.; Einsele, H.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
    Journal Article

    Smit, E. F.; Felip, E.; Uprety, D.; Nagasaka, M.; Nakagawa, K.; Paz-Ares Rodríguez, L.; Pacheco, J. M.; Li, B. T.; Planchard, D.; Baik, C.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
    Review

    Browne, I. M.; André, F.; Chandarlapaty, S.; Carey, L. A.; Turner, N. C.
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): A phase 3, multicentre, open-label trial
    Journal Article

    Mahadeo, K. M.; Baiocchi, R.; Beitinjaneh, A.; Chaganti, S.; Choquet, S.; Dierickx, D.; Dinavahi, R.; Duan, X.; Gamelin, L.; Ghobadi, A.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save